The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Coronary artery disease (CAD) is a major global health concern, with atherosclerotic plaques necessitating interventions like percutaneous coronary intervention.
• Small vessel disease accounts for a significant portion of these interventions, yet presents higher risks of restenosis and adverse cardiac events.
• First-generation drug-eluting stents (DES) reduced restenosis but introduced concerns of late stent thrombosis, necessitating advancements in stent technology.

Purpose of the Study:

• To review the performance of the cobalt-chromium everolimus-eluting stent (CoCr-EES) in treating small vessel CAD.
• To evaluate the efficacy and safety of CoCr-EES from preclinical, clinical, and pathological viewpoints.
• To highlight key findings regarding stent selection in small vessel CAD management.

Main Methods:

• Review of preclinical data on CoCr-EES.
• Analysis of clinical trial outcomes involving CoCr-EES in small vessel CAD.
• Examination of pathological findings related to CoCr-EES implantation in small coronary arteries.

Main Results:

• CoCr-EES demonstrates improved antirestenotic efficacy, crucial for small vessels.
• The stent's design and drug-eluting properties address limitations of earlier DES generations.
• Evidence suggests favorable outcomes and reduced adverse events compared to historical controls in small vessel CAD.

Conclusions:

• The cobalt-chromium everolimus-eluting stent (CoCr-EES) is a significant advancement for treating small vessel coronary artery disease.
• Stent selection, particularly CoCr-EES, plays a vital role in improving long-term patency and clinical outcomes in this patient subgroup.
• Further research and long-term follow-up will continue to refine the use of CoCr-EES in complex interventional scenarios.